Lineage Cell Therapeutics (LCTX) Construction in Progress (2014 - 2019)
Lineage Cell Therapeutics (LCTX) posted quarterly Construction in Progress of $8.9 million for Q1 2019, up 603.31% quarter-over-quarter from $1.3 million in Q4 2018.
Lineage Cell Therapeutics (LCTX) Construction in Progress (2014 - 2019) Analysis & Trends
Lineage Cell Therapeutics' Construction in Progress history runs 6 years deep, the most recent figure standing at $8.9 million for Q1 2019.
- In Q1 2019, Construction in Progress changed N/A year-over-year to $8.9 million; the TTM figure through Mar 2019 stood at $8.9 million (changed N/A YoY), while the FY2018 annual figure was $1.3 million, down 77.08% from the prior year.
- Construction in Progress for Q1 2019 stood at $8.9 million, up from $1.3 million in the prior quarter.
- The five-year high for Construction in Progress was $8.9 million in Q1 2019, with the low at $93000.0 in Q4 2015.
- The 5-year median for Construction in Progress is $1.6 million (2016), against an average of $3.1 million.
- The sharpest annual moves came in 2015 and 2016: Construction in Progress plunged 77.09% in 2015, then surged 117.26% in 2016.
- Lineage Cell Therapeutics' Construction in Progress stood at $93000.0 in 2015, then surged by 1620.43% to $1.6 million in 2016, then jumped by 245.81% to $5.5 million in 2017, then plunged by 77.08% to $1.3 million in 2018, then soared by 603.31% to $8.9 million in 2019.
- Business Quant data shows LCTX's Construction in Progress at $8.9 million in Q1 2019, $1.3 million in Q4 2018, and $5.1 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 152.67 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 8.92 Mn |
| Dec 31, 2018 | 1.27 Mn |
| Sep 30, 2018 | 5.12 Mn |
| Dec 31, 2017 | 5.53 Mn |
| Sep 30, 2016 | 1.60 Mn |
| Jun 30, 2016 | 1.60 Mn |
| Mar 31, 2016 | 1.32 Mn |
| Dec 31, 2015 | 93,000.00 |
| Sep 30, 2015 | 4.60 Mn |
| Jun 30, 2015 | 3.42 Mn |
| Mar 31, 2015 | 606,641.00 |
| Dec 31, 2014 | 406,000.00 |